NOVARTIS AG-REG (1NOVN.MI) Stock Price, Forecast & Analysis
Europe - BIT:1NOVN - CH0012005267 - Common Stock
1NOVN.MI Key Statistics, Chart & Performance
The current stock price of 1NOVN.MI is 113 EUR.
1NOVN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.54 | 213.66B | ||
| SNW.DE | SANOFI | 11.53 | 213.44B | ||
| SAN.PA | SANOFI | 11.48 | 212.51B | ||
| 1MRK.MI | MERCK KGAA | 13.27 | 49.11B | ||
| MRK.DE | MERCK KGAA | 16.08 | 48.31B | ||
| UCB.BR | UCB SA | 36.03 | 44.99B | ||
| BAYN.DE | BAYER AG-REG | 5.54 | 26.77B | ||
| 1BAYN.MI | BAYER AG-REG | 5.55 | 26.81B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.96 | 10.70B | ||
| IPN.PA | IPSEN | 12.51 | 10.77B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 97.36 | 9.01B | ||
| VIRP.PA | VIRBAC SA | 20.67 | 3.01B |
Related stock screener links
About 1NOVN.MI
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
NOVARTIS AG-REG
Lichtstrasse 35
Basel BASEL-STADT CH
Employees: 75883
Phone: 41613241111
NOVARTIS AG-REG / 1NOVN.MI FAQ
What does NOVARTIS AG-REG do?
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
What is the stock price of NOVARTIS AG-REG today?
The current stock price of 1NOVN.MI is 113 EUR. The price increased by 5.61% in the last trading session.
What is the dividend status of NOVARTIS AG-REG?
NOVARTIS AG-REG (1NOVN.MI) has a dividend yield of 3.31%. The yearly dividend amount is currently 3.26.
What is the ChartMill technical and fundamental rating of 1NOVN stock?
1NOVN.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the PE ratio for 1NOVN stock?
The PE ratio for NOVARTIS AG-REG (1NOVN.MI) is 14.68. This is based on the reported non-GAAP earnings per share of 7.7 and the current share price of 113 EUR.
Can you provide the market cap for NOVARTIS AG-REG?
NOVARTIS AG-REG (1NOVN.MI) has a market capitalization of 216.82B EUR. This makes 1NOVN.MI a Mega Cap stock.
1NOVN.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1NOVN.MI.
1NOVN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1NOVN.MI. Both the health and profitability get an excellent rating, making 1NOVN.MI a very profitable company, without any liquidiy or solvency issues.
1NOVN.MI Financial Highlights
Over the last trailing twelve months 1NOVN.MI reported a non-GAAP Earnings per Share(EPS) of 7.7. The EPS increased by 21.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.69% | ||
| ROA | 13.42% | ||
| ROE | 32.47% | ||
| Debt/Equity | 0.55 |
1NOVN.MI Forecast & Estimates
31 analysts have analysed 1NOVN.MI and the average price target is 110.67 EUR. This implies a price decrease of -2.06% is expected in the next year compared to the current price of 113.
For the next year, analysts expect an EPS growth of 16.95% and a revenue growth 9.97% for 1NOVN.MI